While early anecdotal reports suggest high doses of hallucinogens may temporarily alleviate the psychological burden of observing the political landscape, health officials stressed Tuesday that the data is not yet peer-reviewed.
The Trump administration’s sudden pivot toward embracing psychedelics like psilocybin and LSD has prompted a flurry of clinical interest. However, researchers at the National Institutes of Health emphasize that the sample size of cabinet members successfully visualizing a coherent domestic policy remains statistically insignificant. Experts noted that while the correlation between daily microdosing and a sudden belief in functional trickledown economics is robust, causation has not been definitively established in a clinical setting. The agency explicitly warned that substituting evidence-based policymaking with schedule-one narcotics carries unknown pharmacological risks.
While we observe a pronounced reduction in the cohort's baseline distress when asked to perceive actual geopolitical events, we must strictly control for confounding variables such as preexisting cognitive dissonance.
The shift in conservative drug policy follows preliminary phase-one trials in which operatives were administered 25 milligrams of synthetic psilocybin. Although subjects reported profound mystical experiences in which they spoke directly to a benevolent, fully funded border wall, medical journals cautioned that the findings relied heavily on self-reported survey data. Furthermore, longitudinal studies are required to determine if the administration’s pivot to LSD is a safe, long-term intervention for drafting legislation, or merely a transient placebo effect masking underlying structural deficits.
Until robust, double-blind, randomized controlled trials are completed, the American Medical Association advises against relying on psychedelic compounds as a primary mechanism for governance. Health officials warn that the observed ego-death among senior Republican officials could easily reverse within a standard 48-hour pharmacokinetic window, urging the public to interpret the administration's new therapeutic protocol with extreme caution.